ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO930

Hospital Readmissions in Kidney Transplant Recipients with Peripheral Vascular Disease

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Lubetzky, Michelle L., Montefiore Medical Center, New York, New York, United States
  • Kamal, Layla, Montefiore Medical Center, Bronx, New York, United States
  • Ajaimy, Maria, Montefiore Medical Center, Bronx, New York, United States
  • Bedi, Puneet, Brookdale University Hospital Medical Center, Brooklyn, New York, United States
  • Akalin, Enver, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States

The benefits of kidney transplantation (KTx) in diabetic patients with peripheral vascular disease (PVD) are unclear. While patients may have improved survival compared to dialysis, the burden of care post KTx has not been assessed.


We performed a review of diabetic patients with and without PVD transplanted from January 2012 to June 30, 2015. Data on readmissions, re-operations and length of stay was collected. Patient and graft survival was assessed.


Of 203 diabetic patients reviewed 56 (27.6%) had PVD and 147 no PVD. There was no difference in age, sex, race, or type of KTx between the two groups. At a median of 3.14 years follow up (range 30, 1947) there was no difference in 30 or 90 day readmissions between the groups, however significantly more PVD patients were admitted at 1 year (p=0.03), Figure 1. Additionally, PVD patients spent significantly more time in hospital at 1 year (p=0.03). More patients with PVD had re-operations at 90 days and 1 year (p<0.01, p<0.01). Overall graft survival was worse in diabetic patients with PVD although this was not significant (93.2% versus 85.7% p=0.1). Patients with PVD who were re-admitted had significantly worse graft survival than patients with PVD who were not readmitted (100% vs 78.9% p=0.04, Figure 2).


Diabetic patients with PVD have worse graft survival than those without PVD and utilize more resources after KTx with significantly longer length of stays and more re-operations. Readmission in KTx patients with PVD portends poor graft survival.